Trial · NCT06738758
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Lipid attainment rate at each visit node during the observation period (<1.4 mmol/L) | 3 days of medication; At hospital discharge, which is expected to occur between 5 to 10days after admission, depending on the patient's clinical progress; At 1, 3, 6, 12 months after discharge | Lipid attainment rate at each visit node during the observation period (\<1.4 mmol/L) |
| Secondary | The average time for different treatment groups to reach the guideline-recommended lipid standards (<1.4mmol/L) during the observation period. | 3 days of medication; At hospital discharge, which is expected to occur between 5 to 10days after admission, depending on the patient's clinical progress; At 1, 3, 6, 12 months after discharge | The average time for different treatment groups to reach the guideline-recommended lipid standards (\<1.4mmol/L) during the observation period. |
| Secondary | The overall incidence of the first major adverse cardiovascular events (MACEs) within 12 months in different treatment groups | 12 months | Description: MACEs was defined as the composite of myocardial infarction, ischemic stroke, cardiovascular death and coronary revascularization |
| Secondary | Time from in-hospital initiation of lipid-lowering therapy to first occurrence of any of the above clinical events | 12 months | |
| Secondary | Percentage change from baseline in LDL-C across treatment groups at different visit nodes | 3 days of medication; At hospital discharge, which is expected to occur between 5 to 10days after admission, depending on the patient's clinical progress; At 1, 3, 6, 12 months after discharge | |
| Secondary | Change from baseline in inflammatory factors | 3 days of medication; At hospital discharge, which is expected to occur between 5 to 10days after admission, depending on the patient's clinical progress; At 1, 3, 6, 12 months after discharge | Inflammatory factors include IL-6, CRP/Hypersensitive CRP |
| Other | The correlation between LDL-C in-hospital compliance, 1-month compliance, and 3-month compliance with MACE | At hospital discharge, which is expected to occur between 5 to 10days after admission, depending on the patient's clinical progress; At 1, 3, 6, 12 months after discharge | |
| Other | The correlation between the duration of LDL-C within the target and MACE | 12 months | |
| Other | The correlation between different baseline GRACE score levels (low, medium, high) and MACE | 12 months | |
| Other | The correlation between different baseline inflammatory cytokine level groups (quartiles) and MACE | 12 months | |
| Other | The correlation between different baseline age groups (≤ 45 years old or not) and MACE | 12 months | |
| Other | Percentage change in FAI measured by cardiac CT in patients undergoing elective PCI | 12 months | FAI is a quantitative indicator of inflammation in perivascular adipose tissue measured by CCTA. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06738758/registered